Bank of New York Mellon Corp Has $40.23 Million Holdings in Option Care Health, Inc. $OPCH

Bank of New York Mellon Corp decreased its position in Option Care Health, Inc. (NASDAQ:OPCH) by 4.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,238,740 shares of the company’s stock after selling 61,068 shares during the quarter. Bank of New York Mellon Corp’s holdings in Option Care Health were worth $40,234,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of OPCH. Geneva Capital Management LLC raised its position in Option Care Health by 37.4% in the 2nd quarter. Geneva Capital Management LLC now owns 1,073,646 shares of the company’s stock valued at $34,872,000 after buying an additional 292,021 shares during the last quarter. Atria Investments Inc raised its holdings in shares of Option Care Health by 45.3% in the second quarter. Atria Investments Inc now owns 10,898 shares of the company’s stock valued at $354,000 after purchasing an additional 3,397 shares during the last quarter. Assetmark Inc. lifted its position in shares of Option Care Health by 1.6% in the second quarter. Assetmark Inc. now owns 26,690 shares of the company’s stock worth $867,000 after purchasing an additional 416 shares in the last quarter. Whalen Wealth Management Inc. boosted its holdings in Option Care Health by 13.2% during the second quarter. Whalen Wealth Management Inc. now owns 13,831 shares of the company’s stock worth $449,000 after purchasing an additional 1,618 shares during the last quarter. Finally, Jennison Associates LLC grew its position in Option Care Health by 145.6% in the second quarter. Jennison Associates LLC now owns 2,138,248 shares of the company’s stock valued at $69,450,000 after purchasing an additional 1,267,660 shares in the last quarter. 98.05% of the stock is owned by institutional investors and hedge funds.

Option Care Health Trading Up 1.4%

OPCH stock opened at $29.04 on Thursday. Option Care Health, Inc. has a one year low of $21.39 and a one year high of $35.53. The stock has a market cap of $4.61 billion, a price-to-earnings ratio of 23.23, a price-to-earnings-growth ratio of 1.74 and a beta of 0.88. The company has a fifty day moving average price of $27.78 and a two-hundred day moving average price of $29.64. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The company had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.41 billion. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The company’s revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 earnings per share. Option Care Health has set its FY 2025 guidance at 1.680-1.720 EPS. Equities analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current year.

Insiders Place Their Bets

In related news, Director Timothy P. Sullivan acquired 20,000 shares of the business’s stock in a transaction on Thursday, August 21st. The stock was purchased at an average cost of $27.51 per share, for a total transaction of $550,200.00. Following the completion of the transaction, the director directly owned 49,229 shares of the company’s stock, valued at approximately $1,354,289.79. The trade was a 68.43% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Norman L. Wright bought 3,411 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The stock was purchased at an average cost of $29.31 per share, for a total transaction of $99,976.41. Following the transaction, the director directly owned 15,501 shares of the company’s stock, valued at $454,334.31. The trade was a 28.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 97,411 shares of company stock worth $2,614,816 over the last three months. Insiders own 0.64% of the company’s stock.

Wall Street Analysts Forecast Growth

OPCH has been the topic of several analyst reports. TD Cowen cut their price target on shares of Option Care Health from $30.00 to $27.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Option Care Health in a report on Wednesday, October 8th. Barrington Research restated an “outperform” rating and issued a $38.00 price target on shares of Option Care Health in a research note on Friday, October 31st. Citizens Jmp lowered their price target on Option Care Health from $38.00 to $36.00 and set a “market outperform” rating on the stock in a research report on Friday, October 31st. Finally, Cowen began coverage on Option Care Health in a research note on Thursday, October 2nd. They set a “hold” rating on the stock. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.67.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.